Evidence map›Paper›PMID 29441459›Full record

ReviewHormones & cancer2018

Thyroid Hormone in the Clinic and Breast Cancer.

Aleck Hercbergs, Shaker A Mousa, Matthew Leinung, Hung-Yun Lin, Paul J Davis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hormones & cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Is Melanoma Progression Affected by Thyroid Diseases?International journal of molecular sciences · 2022
    Review
  10. Article
  11. Review
  12. Thyroid Diseases and Breast Cancer.Journal of personalized medicine · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aleck HercbergsDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA.
Shaker A MousaPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
Matthew LeinungDepartment of Medicine, Albany Medical College, Albany, NY, USA.
Hung-Yun LinProgram for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Paul J DavisPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA. pdavis.ordwayst@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is preclinical and recent epidemiological evidence that thyroid hormone supports breast cancer. These observations raise the issue of whether management of breast cancer in certain settings should include consideration of reducing the possible contribution of thyroid hormone to the advancement of the disease. In a preliminary experience, elimination of the clinical action of endogenous L-thyroxine (T

Indexed as

Hormone Replacement TherapyAnimalsBreast NeoplasmsCarcinogenesisHumansHypothyroidismThyroid HormonesThyroxineTriiodothyronineThyroid HormonesThyroxineTriiodothyronine

Identifiers

PMID29441459
PMCPMC5945724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.